Brief: Enlivex Announces Dosing Of First Patient Under Phase II Trial For Allocetra
31/07/2023 14:02
July 31 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES DOSING OF FIRST PATIENT UNDER THE
AMENDED
PROTOCOL OF ITS PHASE II TRIAL EVALUATING ALLOCETRA™ IN PATIENTS
WITH SEPSIS
* ENLIVEX THERAPEUTICS LTD - BELIEVE THAT TOP-LINE DATA
READOUT
FROM PHASE II TRIAL WILL BE IN Q1 2024
Source text for Eikon: ID:nGNX8VYPXf
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment